Local failure after complete resection of N0-1 non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorSaynak, Mert
dc.contributor.authorVeeramachaneni, Nirmal K.
dc.contributor.authorHubbs, Jessica L.
dc.contributor.authorNam, Jiho
dc.contributor.authorQaqish, Bahjat F.
dc.contributor.authorBailey, Janet E.
dc.contributor.authorChung, Wonil
dc.date.accessioned2024-06-12T11:09:19Z
dc.date.available2024-06-12T11:09:19Z
dc.date.issued2011
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To estimate the risk of local-regional failure (LRF) after surgery for operable NSCLC, and the effect of clinical/pathologic factors on this risk. Methods: Records of 335 patients undergoing complete resection (lobectomy, pneumonectomy) for pathological T1-4 N0-1 NSCLC (without post-operative radiation) from 1996 to 2006 were reviewed. Crude and actuarial estimated failure rates were computed; local-regional sites included ipsilateral lung, surgical stump, hilar, mediastinal, or supraclavicular nodes. Failure times in sub-groups were calculated with the Kaplan-Meier method and compared via log-rank test. Independent factors adversely affecting LRF were determined with Cox regression. Results: The median follow-up duration for event-free surviving patients was 40 months (range: 1-150). The crude and actuarial 5-year probability of any failure (LR or distant) were 33% and 43%, respectively. Of all failures; 37% were LR only, 35% LR and distant and 28% distant only. The 5-year crude and actuarial probability of LRF were 24% and 35% (95% Cl: 29-42%). Five-year crude LRF rates for T1-2N0, T1-2N1, T3-4N0 and T3-4N1 disease were 19% (41/216), 27% (16/59), 37.5% (15/40) and 40% (8/20), respectively. The corresponding actuarial estimates were T1-2N0 28%, T1-2N1 39%, T3-4N0 50% and T3-4N1 67%. In Cox multiple regression analysis, lymphovascular space invasion (p = 0.03, HR: 1.7) and tumor size (p = 0.01, HR: 1.67 for 5 cm increment) were associated with an increased risk of LRF. Conclusion: Five-year LRF rates are >= 19% in essentially all patient subsets. (C) 2010 Elsevier Ireland Ltd. All rights reserved.en_US
dc.description.sponsorshipTurkish Association of Radiation Oncologyen_US
dc.description.sponsorshipMert Saynak was funded by grants from the Turkish Association of Radiation Oncology.en_US
dc.identifier.doi10.1016/j.lungcan.2010.06.001
dc.identifier.endpage165en_US
dc.identifier.issn0169-5002
dc.identifier.issn1872-8332
dc.identifier.issue2en_US
dc.identifier.pmid20615576en_US
dc.identifier.scopus2-s2.0-78650940701en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage156en_US
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2010.06.001
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22773
dc.identifier.volume71en_US
dc.identifier.wosWOS:000287769400006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofLung Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectSurgeryen_US
dc.subjectLocal-Regional Failureen_US
dc.subjectDistant Failureen_US
dc.subjectPatterns Of Failureen_US
dc.subjectPostoperative Radiotherapyen_US
dc.subjectPostoperative Radiation-Therapyen_US
dc.subjectTrialist Association Anitaen_US
dc.subjectStage-Ien_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectRandomized-Trialen_US
dc.subjectRecurrenceen_US
dc.subjectRadiotherapyen_US
dc.subjectCarcinomaen_US
dc.subjectSurvivalen_US
dc.subjectLobectomyen_US
dc.titleLocal failure after complete resection of N0-1 non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu